首页> 美国卫生研究院文献>Journal of Virology >A Single Immunization with CoVaccine HT-Adjuvanted H5N1 Influenza Virus Vaccine Induces Protective Cellular and Humoral Immune Responses in Ferrets
【2h】

A Single Immunization with CoVaccine HT-Adjuvanted H5N1 Influenza Virus Vaccine Induces Protective Cellular and Humoral Immune Responses in Ferrets

机译:CoVaccine HT佐剂H5N1流感病毒疫苗的单次免疫诱导雪貂的保护性细胞和体液免疫反应。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Highly pathogenic avian influenza A viruses of the H5N1 subtype continue to circulate in poultry, and zoonotic transmissions are reported frequently. Since a pandemic caused by these highly pathogenic viruses is still feared, there is interest in the development of influenza A/H5N1 virus vaccines that can protect humans against infection, preferably after a single vaccination with a low dose of antigen. Here we describe the induction of humoral and cellular immune responses in ferrets after vaccination with a cell culture-derived whole inactivated influenza A virus vaccine in combination with the novel adjuvant CoVaccine HT. The addition of CoVaccine HT to the influenza A virus vaccine increased antibody responses to homologous and heterologous influenza A/H5N1 viruses and increased virus-specific cell-mediated immune responses. Ferrets vaccinated once with a whole-virus equivalent of 3.8 μg hemagglutinin (HA) and CoVaccine HT were protected against homologous challenge infection with influenza virus A/VN/1194/04. Furthermore, ferrets vaccinated once with the same vaccine/adjuvant combination were partially protected against infection with a heterologous virus derived from clade 2.1 of H5N1 influenza viruses. Thus, the use of the novel adjuvant CoVaccine HT with cell culture-derived inactivated influenza A/H5N1 virus antigen is a promising and dose-sparing vaccine approach warranting further clinical evaluation.
机译:H5N1亚型的高致病性禽流感A病毒继续在禽类中传播,并经常报告人畜共患病的传播。由于仍然担心由这些高致病性病毒引起的大流行,因此人们对开发可以保护人类免受感染的A / H5N1流感病毒疫苗感兴趣,最好是在单次接种低剂量抗原后进行保护。在这里,我们描述了用新的佐剂CoVaccine HT结合细胞培养衍生的全灭活甲型流感病毒疫苗接种后在雪貂中诱导的体液和细胞免疫反应。向甲型流感病毒疫苗中添加CoVaccine HT可以提高对同源和异源甲型A / H5N1流感病毒的抗体反应,并增加病毒特异性细胞介导的免疫反应。用全病毒当量3.8μg血凝素(HA)和CoVaccine HT接种过一次的雪貂受到保护,不会受到A / VN / 1194/04流感病毒的同源攻击。此外,用相同的疫苗/佐剂组合接种过一次的雪貂受到了部分保护,以防止感染源自H5N1流感病毒进化枝2.1的异源病毒。因此,将新型佐剂CoVaccine HT与细胞培养衍生的灭活的A / H5N1流感病毒抗原结合使用是一种有前途且节省剂量的疫苗,需要进一步的临床评估。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号